GW-0742
The Next-Generation PPARδ Agonist
01
Overview
GW-0742 is a potent and selective PPARδ (peroxisome proliferator-activated receptor delta) agonist developed by GlaxoSmithKline as a successor to GW-501516 (Cardarine). It demonstrates approximately 100-fold greater PPARδ selectivity over PPARα and PPARγ. Research examines its effects on fatty acid oxidation, skeletal muscle adaptation, neuroprotection, and metabolic disease.
02
Mechanism of Action
GW-0742 binds PPARδ with high affinity (EC50 ~1 nM), forming a heterodimer with RXR that activates metabolic gene programs. It upregulates genes for fatty acid transport (CPT1), β-oxidation enzymes, and mitochondrial biogenesis via PGC-1α. It also suppresses NF-κB-driven inflammatory gene expression in endothelial and macrophage cells.
03
Research Highlights
Comparative studies show superior PPARδ selectivity versus GW-501516 with comparable metabolic effects
Neuroprotection research demonstrates reduced neuronal death in ischemia and Parkinson models
Endothelial inflammation studies show reduced adhesion molecule expression and vascular protection
04
Dosage
Administration & Timing
Oral administration (capsule or solution), once or twice daily. Research protocols administer independent of food.
Dosage Guidelines
Cycle Length
4–8 weeks; research is largely preclinical.
05
Reconstitution
Solvent
Not applicable — orally dosed capsule or solution
Volume
N/A
Concentration
2–10 mg total daily dose
Storage
Store at room temperature (15–25 °C); protect from moisture.
Notes
GW-0742 is a PPARδ/β agonist, more potent than Cardarine. Preclinical — no approved human use.
Research Reference Only
Dosage and reconstitution values reflect commonly cited ranges from published research literature and are presented for educational and research reference only. This is not medical advice or a dosing recommendation. HEXAGEN does not endorse human use of any compound. Always consult a qualified healthcare professional.
Research Disclaimer
GW-0742 is for educational and research purposes only. Not intended as medical advice. Consult a qualified healthcare professional before making any health-related decisions.
Related Compounds
View All
GW-0742 Knowledge Graph
Explore how GW-0742 connects to mechanisms, research goals, related compounds, research stacks, and scientific references. Drag nodes, zoom, and filter by type.
No nodes match the active filters.
GW-0742 — Common Research Questions
What is GW-0742?
GW-0742 is a potent and selective PPARδ (peroxisome proliferator-activated receptor delta) agonist developed by GlaxoSmithKline as a successor to GW-501516 (Cardarine). It demonstrates approximately 1... GW-0742 belongs to the Non-Peptide Research research category and is studied for its the next-generation pparδ agonist.
How does GW-0742 work?
GW-0742 binds PPARδ with high affinity (EC50 ~1 nM), forming a heterodimer with RXR that activates metabolic gene programs. It upregulates genes for fatty acid transport (CPT1), β-oxidation enzymes, and mitochondrial biogenesis via PGC-1α. It also suppresses NF-κB-driven inflammatory gene expression in endothelial and macrophage cells.
What are the key research benefits of GW-0742?
High PPARδ selectivity (1000× over PPARα/γ). Enhanced fatty acid oxidation and metabolic flexibility. Skeletal muscle oxidative fiber transformation. Neuroprotective effects in research models. Anti-inflammatory activity in endothelial tissue. Potential cardiometabolic disease research.
What is the molecular structure of GW-0742?
GW-0742 is a research compound in the Non-Peptide Research category. Detailed molecular structure data is being compiled. Refer to primary literature for structural analysis.
What does the research say about GW-0742?
Comparative studies show superior PPARδ selectivity versus GW-501516 with comparable metabolic effects Neuroprotection research demonstrates reduced neuronal death in ischemia and Parkinson models Endothelial inflammation studies show reduced adhesion molecule expression and vascular protection These findings are based on preclinical and clinical research. GW-0742 is a research compound and these studies do not constitute medical advice.
Is GW-0742 FDA approved?
No. GW-0742 is not FDA-approved for any indication. It is a research chemical studied in preclinical and early clinical research. These compounds are not approved for human therapeutic use and should only be studied in appropriate research settings.
What category does GW-0742 belong to?
GW-0742 belongs to the Non-Peptide Research category, which focuses on selective androgen receptor modulators and other novel research compounds studied for their unique pharmacological profiles. You can explore more compounds in this category on the Non-Peptide Research pillar page.
Related Articles
RAD-140 (Testolone): Selective Anabolic Activity
Examining RAD-140's tissue-selective androgen receptor binding and its Phase I breast cancer research.
Cardarine (GW501516): PPARδ and Exercise Mimetics
How Cardarine activates PPARδ to drive fatty acid oxidation and its implications for endurance research.
LGD-4033 (Ligandrol): Phase I Clinical Data
Viking Therapeutics' Phase I trial showing dose-dependent lean mass gains and the VK5211 hip fracture study.
Scientific References
Comparative studies show superior PPARδ selectivity versus GW-501516 with comparable metabolic effects
Neuroprotection research demonstrates reduced neuronal death in ischemia and Parkinson models
Endothelial inflammation studies show reduced adhesion molecule expression and vascular protection